Pathogenic Germline Variant

SAN ANTONIO — In this video, Halle Moore, MD, discusses the long-term results of the OlympiA trial presented at San Antonio Breast Cancer Symposium.

SAN ANTONIO — In this video, Judy Garber, MD, MPH, discusses the results of the OlympiA trial presented at San Antonio Breast Cancer Symposium.

In this edition, germline testing ‘should be considered’ for all patients with lung cancer; phase 3 trial of canakinumab misses endpoint; sexual dysfunction common among women with lung cancer, and more.

Clinical trial accrual rates have dropped 20% since the start of the COVID-19 pandemic and staffing shortages have slowed progress in cancer research, according to the Society for Immunotherapy of Cancer.

About 15% of a large cohort of patients with lung cancer had pathogenic germline variants, nearly all of which could be clinically actionable, according to study results presented during an ASCO Plenary Series session.

Researchers found no clinically meaningful differences in the prevalence of germline pathogenic variants in a dozen breast cancer risk genes between Black and white women with breast cancer, according to a study published in JAMA Oncology.

Complete immunohistochemistry diagnostics reduced the need for subsequent gene testing in patients with Lynch syndrome, according to research published in Clinical Gastroenterology and Hepatology.

Multi-gene panel testing in colorectal cancer led to significant detection of heritable gene mutations compared with guideline-based testing, according to research published in Clinical Gastroenterology and Hepatology.